Incretin Atlas › Trials › TRIUMPH-4 (obesity + knee osteoarthritis)
TRIUMPH-4 (obesity + knee osteoarthritis)
Retatrutide · obesity
Design
- Molecule(s)
- Retatrutide
- Population
- obesity
- Phase
- 3
- Participants
- 148
- Duration
- 68 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| retatrutide 9 mg | obesity | 68 | 148 | −26.4 % vs −2.1 % Δ −24.3 pp | −20.0 % vs −4.6 % Δ −15.4 pp | — | 12.9 vs 4.0 | — | — | — | 9.5 vs 2.0 | — | verified |
| retatrutide 12 mg | obesity | 68 | 148 | −28.7 % vs −2.1 % Δ −26.6 pp | −23.7 % vs −4.6 % Δ −19.1 pp | — | 18.2 vs 4.0 | — | — | — | 10.8 vs 2.0 | −14.0 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- retatrutide 9 mg: Peer-reviewed paper (NEJM, November 2026): n, treatment-regimen weight, AE discontinuation and SAE from Tables 2–3. Efficacy-estimand weight and SBP still from the December 2025 topline release (Supplementary Tables S8/S11 not yet in hand); nausea and vomiting are in Supplementary Table S12. AE discontinuation: Table 3 gives 19/147 (12.9 %), the Results text 18/148 (12.2 %); the table value is shown.
- retatrutide 12 mg: Peer-reviewed paper (NEJM, November 2026): n, treatment-regimen weight, AE discontinuation and SAE from Tables 2–3. Efficacy-estimand weight and SBP still from the December 2025 topline release (Supplementary Tables S8/S11 not yet in hand); nausea and vomiting are in Supplementary Table S12.
Verbatim quotes from the source (9)
- retatrutide 9 mg · weight_eff · Article body, paragraph 4
while those on 9 mg lost 26.4%
- retatrutide 9 mg · ae_dc · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
Adverse events 19 27 (18.2) 6 (4.0) 52 (11.7) 4 (2.8) 12 (8.4) 22 (15.3) 9 (6.2) 47 (8.2) leading to (12.9)
- retatrutide 9 mg · weight_tp · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 2
-20.0 (0.9) -23.7 (1.0) -4.6
- retatrutide 9 mg · sae · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
Serious adverse 14 (9.5) 16 (10.8) 3 (2.0) 33 (7.4) 6 (4.2) 14 (9.8) 21 (14.6) 10 (6.9) 51 (8.9)
- retatrutide 12 mg · weight_eff · Article body, paragraph 4
patients receiving the 12 mg dose losing an average of 28.7% of their body weight
- retatrutide 12 mg · ae_dc · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
Adverse events 19 27 (18.2) 6 (4.0)
- retatrutide 12 mg · sbp · The Phase 3 TRIUMPH-4 Trial, paragraph 3
At the highest dose, systolic blood pressure decreased by 14.0 mm Hg.
- retatrutide 12 mg · weight_tp · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 2
-20.0 (0.9) -23.7 (1.0) -4.6
- retatrutide 12 mg · sae · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
Serious adverse 14 (9.5) 16 (10.8) 3 (2.0)
Primary sources
- Schnitzer TJ, Hunter DJ, Conaghan PG, Sharma AM, Pedersen SD, Chen K, et al. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. N Engl J Med. 2026. PMID: 43001755.
- Eli Lilly and Company. TRIUMPH-4 topline results [press release coverage]. 2025 Dec 11. Available from: https://www.pharmexec.com/view/lilly-retatrutide-positive-topline-results-successful-phase-iii-trial
- Retatrutide achieves up to 28.7% weight loss and marked knee pain reduction in phase 3 TRIUMPH-4 trial. Patient Care. 2025 Dec 11. Available from: https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial
How to cite this page
Medical Adviser's Group. Incretin Atlas: TRIUMPH-4 (obesity + knee osteoarthritis). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-4/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.